NASDAQ:SANA Sana Biotechnology (SANA) Stock Price, News & Analysis $2.35 -0.01 (-0.42%) Closing price 10/21/2026 04:00 PM EasternExtended Trading$2.38 +0.03 (+1.23%) As of 10/21/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Sana Biotechnology Stock (NASDAQ:SANA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sana Biotechnology alerts:Sign Up Key Stats Today's Range$2.32▼$2.3950-Day Range$2.27▼$4.1652-Week Range$2.22▼$5.90Volume2.40 million shsAverage Volume3.47 million shsMarket Capitalization$703.50 millionP/E RatioN/ADividend YieldN/APrice Target$9.33Consensus RatingModerate Buy Company Overview Sana Biotechnology, Inc. is a clinical-stage biotechnology company focused on developing engineered cell and gene therapies for serious diseases. The company’s approach is designed to create durable treatments by modifying cells outside or inside the body and using them to replace, repair, or supplement damaged or missing biological functions. Sana is developing proprietary technologies intended to support the delivery and persistence of therapeutic cells. These include platforms for engineering cells to evade immune-system detection, potentially allowing donor-derived cells to be used without extensive immune suppression, as well as methods for delivering genetic instructions directly to targeted tissues. Its research programs have included cell therapies for oncology, autoimmune disorders, diabetes, and other conditions. Founded in 2018 and headquartered in Seattle, Washington, Sana operates as a research and development company and does not have commercially marketed products. The company’s programs remain subject to clinical testing and regulatory review. Steve Harr serves as Sana Biotechnology’s president and chief executive officer.AI Generated. May Contain Errors. Read More Sana Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreSANA MarketRank™: 2.826987307945 of 5 starsSana Biotechnology scored higher than 57% of companies evaluated by MarketBeat, and ranked 346th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingSana Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSana Biotechnology has a consensus price target of $9.33, representing about 297.2% upside from its current price of $2.35.Amount of Analyst CoverageSana Biotechnology has only been the subject of 2 research reports in the past 90 days.Read more about Sana Biotechnology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sana Biotechnology are expected to grow in the coming year, from ($0.72) to ($0.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sana Biotechnology is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sana Biotechnology is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSana Biotechnology has a P/B Ratio of 3.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sana Biotechnology's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted17.34% of the float of Sana Biotechnology has been sold short.Short Interest Ratio / Days to CoverSana Biotechnology has a short interest ratio ("days to cover") of 8.96.Change versus previous monthShort interest in Sana Biotechnology has recently decreased by 6.40%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSana Biotechnology does not currently pay a dividend.Dividend GrowthSana Biotechnology does not have a long track record of dividend growth. News and Social Media1.9 / 5News SentimentN/A News SentimentSana Biotechnology has a news sentiment score of -0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Sana Biotechnology this week, compared to 3 articles on an average week.Search Interest14 people have searched for SANA on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat Follows11 people have added Sana Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 450% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sana Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders25.40% of the stock of Sana Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.23% of the stock of Sana Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sana Biotechnology's insider trading history. Receive SANA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sana Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SANA Stock News HeadlinesSana Biotechnology: A Shot At DiabetesOctober 13, 2026 | seekingalpha.com6 'moonshot' biotech stocks that offer big risks, bigger rewardsSeptember 23, 2026 | msn.comSpaceX is worth trillions. This one's $14.It is not SpaceX, Tesla, Starlink, or Neuralink. But Elon's rocket company shows up in this stock's paperwork, and anyone with a brokerage account can buy shares for about 14 dollars. When SpaceX went public, roughly 4,400 employees became what Dylan Jovine calls the first wave of Space Millionaires. He believes a second wave begins December 8th, when the lockup ends. | Behind the Markets (Ad)Sana Biotechnology (SANA)September 23, 2026 | es.investing.comSana Biotechnology, Inc. (SANA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks TranscriptSeptember 15, 2026 | seekingalpha.comSana Biotechnology op Morgan Stanley conferentie: focus op diabetesSeptember 15, 2026 | nl.investing.comSana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14, 2026 | seekingalpha.comSana Biotechnology出席富国银行医疗健康大会：两大核心项目即将进入临床阶段September 10, 2026 | cn.investing.comSee More Headlines SANA Stock Analysis - Frequently Asked Questions How have SANA shares performed this year? Sana Biotechnology's stock was trading at $4.07 on January 1st, 2026. Since then, SANA stock has decreased by 42.3% and is now trading at $2.35. How were Sana Biotechnology's earnings last quarter? Sana Biotechnology, Inc. (NASDAQ:SANA) posted its earnings results on Monday, August, 10th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.02. When did Sana Biotechnology IPO? Sana Biotechnology (SANA) raised $552 million in an IPO on Wednesday, February 3rd 2021. The company issued 23,500,000 shares at $23.00-$24.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities acted as the underwriters for the IPO. Who are Sana Biotechnology's major shareholders? Sana Biotechnology's top institutional shareholders include Abel Hall LLC. Insiders that own company stock include Robert Nelsen, Fmr Llc and Richard Mulligan. View institutional ownership trends. How do I buy shares of Sana Biotechnology? Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sana Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sana Biotechnology investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Micron Technology (MU), Archer Aviation (ACHR), Advanced Micro Devices (AMD), D-Wave Quantum (QBTS) and SoFi Technologies (SOFI). Company Calendar Last Earnings8/10/2026Today10/22/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 4 weeks, SANA's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SANA CIK1770121 Websana.com Phone206-701-7914FaxN/AEmployees142Year Founded2018Price Target and Rating Average Price Target for Sana Biotechnology$9.33 High Price Target$16.00 Low Price Target$6.00 Potential Upside/Downside+297.2%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$244.17 million Net MarginsN/A Pretax MarginN/A Return on Equity-103.02% Return on Assets-39.16% Debt Debt-to-Equity RatioN/A Current Ratio1.38 Quick Ratio1.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / Book3.92Miscellaneous Outstanding Shares299,360,000Free Float223,323,000Market Cap$703.50 million OptionableOptionable Beta2.18 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:SANA) was last updated on 10/21/2026 by MarketBeat.com Staff. From Our PartnersMicroscopic footage reveals immune cells destroying cancer cellsTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | Sponsored80 Days Until the Pentagon Restricts Chinese Rare EarthsChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sana Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sana Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
